Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Shock. 2022 Jan 1;57(1):24–30. doi: 10.1097/SHK.0000000000001826

Figure 2.

Figure 2.

Changes in Toll-like receptor 4 (TLR4) signaling in canonical myeloid differentiation primary response 88 (MyD88)-mediated signaling pathways. Presented as fold change relative to healthy controls, which were normalized to a baseline of zero. NFκB = nuclear factor kappa B; IL-6 = interleukin 6; IL-6R = interleukin 6 receptor; TNFa = tumor necrosis factor alpha; IL-1b = interleukin 1 beta; *p<0.05 vs. healthy controls; #p<0.05 elective hip replacement vs. trauma patients